CD5 provides viability signals to B cells from a subset of B-CLL patients by a mechanism that involves PKC

Leukemia Research

Volumn 31, Issue 2, 2007, Pages 183-193

  Perez Chacon, Gema ^a   Vargas, Juan A ^b   Jorda, Julia ^c   Morado, Marta ^d   Rosado, Silvia ^a   Martin Donaire, Trinidad ^b   Losada Fernandez, Ignacio ^a   Rebolleda, Nerea ^a   Perez Aciego, Paloma ^a  

^a Fundacion LAIR   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Apoptosis; B cells; B CLL; Kinases Phosphatases; Signal transduction

Indexed keywords

ANTIBODY; CD5 ANTIBODY; CD5 ANTIGEN; CYTOKINE; INTERLEUKIN 10; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN MCL 1; PROTEIN TYROSINE KINASE; X LINKED INHIBITOR OF APOPTOSIS;

ANTIGEN BINDING; ARTICLE; AUTOCRINE EFFECT; B LYMPHOCYTE ACTIVATION; BIOCHEMISTRY; CANCER PATIENT; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DOWNSTREAM PROCESSING; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOREGULATION; LEUKEMIA CELL; LEUKEMOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME;

ANTIGENS, CD5; APOPTOSIS; B-LYMPHOCYTES; CELL SURVIVAL; CELLS, CULTURED; HUMANS; INTERLEUKIN-10; LEUKEMIA, B-CELL, CHRONIC; NEOPLASM PROTEINS; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

EID: 33845198717     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.03.021     Document Type: Article

References (74)

1. Keating M.J., Chiorazzi N., Messmer B., Damle R.N., Allen S.L., Rai K.R., et al. Biology and treatment of chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program) (2003) 153-175
2. Chiorazzi N., Rai K.R., and Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 352 8 (2005) 804-815
3. Lagneaux L., Delforge A., Bron D., De B.C., and Stryckmans P. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 91 7 (1998) 2387-2396
4. Caligaris-Cappio F. Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol 123 3 (2003) 380-388
5. Ghia P., Granziero L., Chilosi M., and Caligaris-Cappio F. Chronic B cell malignancies and bone marrow microenvironment. Semin Cancer Biol 12 2 (2002) 149-155
6. Youinou P., Jamin C., and Lydyard P.M. CD5 expression in human B-cell populations. Immunol Today 20 7 (1999) 312-316
7. Van de Velde H., von Hoegen I., Luo W., Parnes J.R., and Thielemans K. The B-cell surface protein CD72/Lyb-2 is the ligand for CD5. Nature 351 6328 (1991) 662-665
8. Biancone L., Bowen M.A., Lim A., Aruffo A., Andres G., and Stamenkovic I. Identification of a novel inducible cell-surface ligand of CD5 on activated lymphocytes. J Exp Med 184 3 (1996) 811-819
9. Bikah G., Lynd F.M., Aruffo A.A., Ledbetter J.A., and Bondada S. A role for CD5 in cognate interactions between T cells and B cells, and identification of a novel ligand for CD5. Int Immunol 10 8 (1998) 1185-1196
10. Pospisil R., Fitts M.G., and Mage R.G. CD5 is a potential selecting ligand for B cell surface immunoglobulin framework region sequences. J Exp Med 184 4 (1996) 1279-1284
11. Pospisil R., Silverman G.J., Marti G.E., Aruffo A., Bowen M.A., and Mage R.G. CD5 is A potential selecting ligand for B-cell surface immunoglobulin: a possible role in maintenance and selective expansion of normal and malignant B cells. Leuk Lymphoma 36 3-4 (2000) 353-365
12. Calvo J., Places L., Padilla O., Vila J.M., Vives J., Bowen M.A., et al. Interaction of recombinant and natural soluble CD5 forms with an alternative cell surface ligand. Eur J Immunol 29 7 (1999) 2119-2129
13. Beyers A.D., Spruyt L.L., and Williams A.F. Molecular associations between the T-lymphocyte antigen receptor complex and the surface antigens CD2, CD4, or CD8 and CD5. Proc Natl Acad Sci USA 89 7 (1992) 2945-2949
14. Lankester A.C., van Schijndel G.M., Cordell J.L., van Noesel C.J., and van Lier R.A. CD5 is associated with the human B cell antigen receptor complex. Eur J Immunol 24 4 (1994) 812-816
15. Perez-Villar J.J., Whitney G.S., Bowen M.A., Hewgill D.H., Aruffo A.A., and Kanner S.B. CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1. Mol Cell Biol 19 4 (1999) 2903-2912
16. Lozano F., Simarro M., Calvo J., Vila J.M., Padilla O., Bowen M.A., et al. CD5 signal transduction: positive or negative modulation of antigen receptor signaling. Crit Rev Immunol 20 4 (2000) 347-358
17. Azzam H.S., DeJarnette J.B., Huang K., Emmons R., Park C.S., Sommers C.L., et al. Fine tuning of TCR signaling by CD5. J Immunol 166 9 (2001) 5464-5472
18. Tarakhovsky A., Kanner S.B., Hombach J., Ledbetter J.A., Muller W., Killeen N., et al. A role for CD5 in TCR-mediated signal transduction and thymocyte selection. Science 269 5223 (1995) 535-537
19. Tarakhovsky A., Turner M., Schaal S., Mee P.J., Duddy L.P., Rajewsky K., et al. Defective antigen receptor-mediated proliferation of B and T cells in the absence of Vav. Nature 374 6521 (1995) 467-470
20. Bikah G., Carey J., Ciallella J.R., Tarakhovsky A., and Bondada S. CD5-mediated negative regulation of antigen receptor-induced growth signals in B-1 B cells. Science 274 5294 (1996) 1906-1909
21. Alberola-Ila J., Takaki S., Kerner J.D., and Perlmutter R.M. Differential signaling by lymphocyte antigen receptors. Annu Rev Immunol 15 (1997) 125-154
22. Sen G., Bikah G., Venkataraman C., and Bondada S. Negative regulation of antigen receptor-mediated signaling by constitutive association of CD5 with the SHP-1 protein tyrosine phosphatase in B-1 B cells. Eur J Immunol 29 10 (1999) 3319-3328
23. 2+/calmodulin-dependent kinase type IV is involved in the CD5-mediated signaling pathway in human T lymphocytes. J Biol Chem 272 50 (1997) 31809-31820
24. Gringhuis S.I., de Leij L.F., Coffer P.J., and Vellenga E. Signaling through CD5 activates a pathway involving phosphatidylinositol 3-kinase, Vav, and Rac1 in human mature T lymphocytes. Mol Cell Biol 18 3 (1998) 1725-1735
25. Simarro M., Calvo J., Vila J.M., Places L., Padilla O., Alberola-Ila J., et al. Signaling through CD5 involves acidic sphingomyelinase, protein kinase C-zeta, mitogen-activated protein kinase kinase, and c-Jun NH2-terminal kinase. J Immunol 162 9 (1999) 5149-5155
26. Cerutti A., Trentin L., Zambello R., Sancetta R., Milani A., Tassinari C., et al. The CD5/CD72 receptor system is coexpressed with several functionally relevant counterstructures on human B cells and delivers a critical signaling activity. J Immunol 157 5 (1996) 1854-1862
27. Cioca D.P., and Kitano K. Apoptosis induction by hypercross-linking of the surface antigen CD5 with anti-CD5 monoclonal antibodies in B cell chronic lymphocytic leukemia. Leukemia 16 3 (2002) 335-343
28. Pers J.O., Berthou C., Porakishvili N., Burdjanadze M., Le Calvez G., Abgrall J.F., et al. CD5-induced apoptosis of B cells in some patients with chronic lymphocytic leukemia. Leukemia 16 1 (2002) 44-52
29. Cuni S., Perez-Aciego P., Perez-Chacon G., Vargas J.A., Sanchez A., Martin-Saavedra F.M., et al. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 18 8 (2004) 1391-1400
30. Renaudineau Y., Nedellec S., Berthou C., Lydyard P.M., Youinou P., and Pers J.O. Role of B-cell antigen receptor-associated molecules and lipid rafts in CD5-induced apoptosis of B CLL cells. Leukemia 19 2 (2005) 223-229
31. Rozman C., and Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 333 16 (1995) 1052-1057
32. Aman P., Gordon J., Lewin N., Nordstrom M., Ehlin-Henriksson B., Klein G., et al. Surface marker characterization of EBV target cells in normal blood and tonsil B lymphocyte populations. J Immunol 135 4 (1985) 2362-2367
33. Hawkins R.E., Zhu D., Ovecka M., Winter G., Hamblin T.J., Long A., et al. Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. Blood 83 11 (1994) 3279-3288
34. Pers J.O., Jamin C., Le Corre R., Lydyard P.M., and Youinou P. Ligation of CD5 on resting B cells, but not on resting T cells, results in apoptosis. Eur J Immunol 28 12 (1998) 4170-4176
35. Damle R.N., Wasil T., Fais F., Ghiotto F., Valetto A., Allen S.L., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94 6 (1999) 1840-1847
36. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G., and Stevenson F.K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94 6 (1999) 1848-1854
37. Raman C., and Kimberly R.P. Differential CD5-dependent regulation of CD5-associated CK2 activity in mature and immature T cells: implication on TCR/CD3-mediated activation. J Immunol 161 11 (1998) 5817-5820
38. Weiss A., and Littman D.R. Signal transduction by lymphocyte antigen receptors. Cell 76 2 (1994) 263-274
39. Laytragoon-Lewin N., Rossmann E.D., Castro J., and Mellstedt H. Significance of phosphotyrosine proteins, Bcl-2 and p53 for apoptosis in resting B-chronic lymphocytic leukemia (CLL) cells. Int J Cancer 97 3 (2002) 344-348
40. Lanham S., Hamblin T., Oscier D., Ibbotson R., Stevenson F.K., and Packham G. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 101 3 (2002) 1087-1093
41. Contri A., Brunati A.M., Trentin L., Cabrelle A., Miorin M., Cesaro L., et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 115 2 (2005) 369-378
42. Carballo E., Colomer D., Vives Corrons J.L., Blackshear P.J., and Gil J. Phosphorylation of the MARCKS family of protein kinase C substrates in human B chronic lymphocytic leukemia cells. Leukemia 9 5 (1995) 834-839
43. Barragan M., Bellosillo B., Campas C., Colomer D., Pons G., and Gil J. Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells. Blood 99 8 (2002) 2969-2976
44. Ringshausen I., Schneller F., Bogner C., Hipp S., Duyster J., Peschel C., et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood 100 10 (2002) 3741-3748
45. Petlickovski A., Laurenti L., Li X., Marietti S., Chiusolo P., Sica S., et al. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B-cells. Blood 105 12 (2005) 4820-4827
46. Hanada M., Delia D., Aiello A., Stadtmauer E., and Reed J.C. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 82 6 (1993) 1820-1828
47. Kitada S., Andersen J., Akar S., Zapata J.M., Takayama S., Krajewski S., et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood 91 9 (1998) 3379-3389
48. Pistoia V. Production of cytokines by human B cells in health and disease. Immunol Today 18 7 (1997) 343-350
49. Gary-Gouy H., Harriague J., Bismuth G., Platzer C., Schmitt C., and Dalloul A.H. Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. Blood 100 13 (2002) 4537-4543
50. Schroeder Jr. H.W., and Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today 15 6 (1994) 288-294
51. Damle R.N., Batliwalla F.M., Ghiotto F., Valetto A., Albesiano E., Sison C., et al. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by Ig V gene mutations. Blood 103 2 (2004) 375-382
52. Crespo M., Bosch F., Villamor N., Bellosillo B., Colomer D., Rozman M., et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348 18 (2003) 1764-1775
53. Granziero L., Ghia P., Circosta P., Gottardi D., Strola G., Geuna M., et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 97 9 (2001) 2777-2783
54. Lankester A.C., van S.G., van-der S.C., van O.M., van N.C., and van L.R. Antigen receptor nonresponsiveness in chronic lymphocytic leukemia B cells. Blood 86 3 (1995) 1071-1090
55. Bernal A., Pastore R.D., Asgary Z., Keller S.A., Cesarman E., Liou H.C., et al. Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood 98 10 (2001) 3050-3057
56. Zupo S., Massara R., Dono M., Rossi E., Malavasi F., Cosulich M.E., et al. Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD. Blood 95 4 (2000) 1199-1206
57. Chen L., Widhopf G., Huynh L., Rassenti L., Rai K.R., Weiss A., et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 100 13 (2002) 4609-4614
58. Pospisil R., and Mage R.G. CD5 and other superantigens as 'ticklers' of the B-cell receptor. Immunol Today 19 3 (1998) 106-108
59. Kitada S., Zapata J.M., Andreeff M., and Reed J.C. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 106 4 (1999) 995-1004
60. Kitada S., Andersen J., Akar S., Zapata J.M., Takayama S., Krajewski S., et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood 91 9 (1998) 3379-3389
61. Mischak H., Kolch W., Goodnight J., Davidson W.F., Rapp U., Rose-John S., et al. Expression of protein kinase C genes in hemopoietic cells is cell-type- and B cell-differentiation stage specific. J Immunol 147 11 (1991) 3981-3987
62. Huang R.W., Tsuda H., and Takatsuki K. Interleukin-2 prevents programmed cell death in chronic lymphocytic leukemia cells. Int J Hematol 58 1-2 (1993) 83-92
63. Mainou Fowler T., Copplestone J.A., and Prentice A.G. Effect of interleukins on the proliferation and survival of B cell chronic lymphocytic leukaemia cells [see comments]. J Clin Pathol 48 5 (1995) 482-487
64. Levy Y., and Brouet J.C. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Invest 93 1 (1994) 424-428
65. Defrance T., Vanbervliet B., Briere F., Durand I., Rousset F., and Banchereau J. Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J Exp Med 175 3 (1992) 671-682
66. Rousset F., Garcia E., Defrance T., Peronne C., Vezzio N., Hsu D.H., et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 89 5 (1992) 1890-1893
67. Fluckiger A.C., Garrone P., Durand I., and Galizzi J.P. Banchereau J. Interleukin 10 (IL-10) upregulates functional high affinity IL-2 receptors on normal and leukemic B lymphocytes. J Exp Med 178 5 (1993) 1473-1481
68. Ishida H., Hastings R., Kearney J., and Howard M. Continuous anti-interleukin 10 antibody administration depletes mice of Ly-1 B cells but not conventional B cells. J Exp Med 175 5 (1992) 1213-1220
69. Fluckiger A.C., Durand I., and Banchereau J. Interleukin 10 induces apoptotic cell death of B-chronic lymphocytic leukemia cells. J Exp Med 179 1 (1994) 91-99
70. Castejon R., Vargas J.A., Romero Y., Briz M., Munoz R.M., and Durantez A. Modulation of apoptosis by cytokines in B-cell chronic lymphocytic leukemia. Cytometry 38 5 (1999) 224-230
71. Jurlander J., Lai C.F., Tan J., Chou C.C., Geisler C.H., Schriber J., et al. Characterization of interleukin-10 receptor expression on B-cell chronic lymphocytic leukemia cells. Blood 89 11 (1997) 4146-4152
72. Van Kooten C., Rensink I., Aarden L., and van Oers R. Interleukin-4 inhibits both paracrine and autocrine tumor necrosis factor-alpha-induced proliferation of B chronic lymphocytic leukemia cells. Blood 80 5 (1992) 1299-1306
73. Trentin L., Zambello R., Agostini C., Enthammer C., Cerutti A., Adami F., et al. Expression and regulation of tumor necrosis factor, interleukin-2, and hematopoietic growth factor receptors in B-cell chronic lymphocytic leukemia. Blood 84 12 (1994) 4249-4256
74. Berland R., and Wortis H.H. Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol 20 (2002) 253-300